{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:33:05Z","timestamp":1794022385017,"version":"4.8.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.abd.2023.10.002","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T20:24:30Z","timestamp":1711139070000},"page":"546-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeted therapy for immune mediated skin diseases. What should a dermatologist know?"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-7836","authenticated-orcid":false,"given":"Edinson","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0180-9130","authenticated-orcid":false,"given":"Ra\u00fal","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8509-1188","authenticated-orcid":false,"given":"Crist\u00f3bal","family":"Lecaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2023.10.002_bib0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: history and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr Opin Pharmacol."},{"key":"10.1016\/j.abd.2023.10.002_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1570163811666140121154649","article-title":"Different approaches for obtaining antibodies from human B cells","volume":"11","author":"Duvall","year":"2014","journal-title":"Curr Drug Discov Technol."},{"key":"10.1016\/j.abd.2023.10.002_bib0015","series-title":"Dermatology","first-page":"2880","author":"Bolognia","year":"2017"},{"key":"10.1016\/j.abd.2023.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2174\/1381612824666180327165604","article-title":"Signaling pathways in inflammation and anti-inflammatory therapies","volume":"24","author":"Yeung","year":"2018","journal-title":"Curr Pharm Des."},{"key":"10.1016\/j.abd.2023.10.002_bib0025","series-title":"Biologic and systemic agents in dermatology","first-page":"1","author":"Yamauchi","year":"2018"},{"issue":"345","key":"10.1016\/j.abd.2023.10.002_bib0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"26","author":"Ellis","year":"2001","journal-title":"N Engl J Med."},{"issue":"290","key":"10.1016\/j.abd.2023.10.002_bib0035","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1001\/jama.290.23.3073","article-title":"Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"17","author":"Gordon","year":"2003","journal-title":"JAMA."},{"issue":"349","key":"10.1016\/j.abd.2023.10.002_bib0040","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"20","author":"Leonardi","year":"2003","journal-title":"N Engl J Med."},{"issue":"357","key":"10.1016\/j.abd.2023.10.002_bib0045","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"9","author":"Chaudhari","year":"2001","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.abd.2023.10.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"323","key":"10.1016\/j.abd.2023.10.002_bib0055","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"19","author":"Armstrong","year":"2020","journal-title":"JAMA."},{"key":"10.1016\/j.abd.2023.10.002_bib0060","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jid.2022.01.014","article-title":"From empirical to pathogenesis-based treatments for psoriasis","volume":"142","author":"van de Kerkhof","year":"2022","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0065","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Barker JNWN","volume":"397","author":"Griffiths","year":"2021","journal-title":"Psoriasis. Lancet."},{"key":"10.1016\/j.abd.2023.10.002_bib0070","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jaad.2011.03.012","article-title":"Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients","volume":"66","author":"Wan","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0075","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaad.2019.04.042","article-title":"Joint American academy of dermatology\u2013national psoriasis foundation guidelines of care for the management and treatment of psoriasis with phototherapy","volume":"81","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jdermsci.2021.01.002","article-title":"Utility of the dermatology life quality index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: results from the ProLOGUE study","volume":"101","author":"Imafuku","year":"2021","journal-title":"J Dermatol Sci."},{"key":"10.1016\/j.abd.2023.10.002_bib0090","first-page":"5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"23","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.abd.2023.10.002_bib0095","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"1","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","article-title":"Long-term benefit\u2013risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther (Heidelb)."},{"key":"10.1016\/j.abd.2023.10.002_bib0105","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1080\/09546634.2021.1959504","article-title":"Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study","volume":"33","author":"Blauvelt","year":"2022","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2023.10.002_bib0110","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1007\/s13555-022-00840-9","article-title":"A review of the clinical trial landscape in psoriasis: an update for clinicians","volume":"12","author":"Drakos","year":"2022","journal-title":"Dermatol Ther (Heidelb)."},{"key":"10.1016\/j.abd.2023.10.002_bib0115","article-title":"A scoping review on use of drugs targeting the JAK\/STAT pathway in psoriasis","volume":"9","author":"G\u00f3mez-Garc\u00eda","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.abd.2023.10.002_bib0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0130","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1080\/09546634.2021.1914306","article-title":"Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis","volume":"33","author":"Xie","year":"2022","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2023.10.002_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2021.06.004","article-title":"Biologics for severe, chronic plaque psoriasis: an Australian cost-utility analysis","volume":"5","author":"Sun","year":"2021","journal-title":"JAAD Int."},{"key":"10.1016\/j.abd.2023.10.002_bib0140","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British association of dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0145","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14974","article-title":"Comparison of guidelines for the use of Ustekinumab for psoriasis in the United States, Europe, and the United Kingdom: a critical appraisal and comprehensive review","volume":"34","author":"Chat","year":"2021","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2023.10.002_bib0150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1684\/ejd.2020.3945","article-title":"Portuguese recommendations for the treatment of psoriasis with biologic therapy","volume":"30","author":"Torres","year":"2020","journal-title":"Eur J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.abd.2023.10.002_bib0160","first-page":"469","article-title":"Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics","volume":"157","author":"Prignano","year":"2022","journal-title":"Ital J Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0165","doi-asserted-by":"crossref","DOI":"10.5070\/D32610050454","article-title":"Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne\/rosacea during the COVID-19 pandemic","volume":"26","author":"Yim","year":"2020","journal-title":"Dermatol Online J."},{"key":"10.1016\/j.abd.2023.10.002_bib0170","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaad.2021.02.057","article-title":"Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data","volume":"85","author":"Shear","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjd.19244","article-title":"Meta-analysis results do not reflect the real safety of biologics in psoriasis","volume":"184","author":"Afach","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0180","first-page":"411","article-title":"New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis","volume":"155","author":"D\u2019Urso","year":"2020","journal-title":"G Ital Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0185","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1346-8138.14096","article-title":"Safety of biologics in psoriasis","volume":"45","author":"Kamata","year":"2018","journal-title":"J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0190","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/bjd.14964","article-title":"Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials","volume":"176","author":"Rungapiromnan","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: a systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0200","first-page":"1","article-title":"Biologics in psoriasis: updated perspectives on long-term safety and risk management","volume":"12","author":"Al-Janabi","year":"2022","journal-title":"Psoriasis (Auckl)."},{"key":"10.1016\/j.abd.2023.10.002_bib0205","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/pde.14870","article-title":"Biologics for pediatric psoriasis: a systematic review and meta-analysis","volume":"39","author":"Sun","year":"2022","journal-title":"Pediatr Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0215","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy."},{"key":"10.1016\/j.abd.2023.10.002_bib0220","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0225","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdv.18345","article-title":"European guideline (EuroGuiDerm) on atopic eczema: part I \u2013 systemic therapy","volume":"36","author":"Wollenberg","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0230","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2023.10.002_bib0235","article-title":"Systemic treatments for eczema: a network meta-analysis","volume":"9","author":"Sawangjit","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.abd.2023.10.002_bib0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/all.14510","article-title":"Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy."},{"key":"10.1016\/j.abd.2023.10.002_bib0245","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2023.10.002_bib0255","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2023.10.002_bib0260","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0265","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.abd.2023.10.002_bib0270","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0275","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0280","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0285","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0290","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0295","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0300","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0305","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0310","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2012.07.012","article-title":"Progressive activation of T(H)2\/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis","volume":"130","author":"Gittler","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0315","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0320","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0325","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0335","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0340","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0345","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jcph.1360","article-title":"Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning","author":"Purohit","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.abd.2023.10.002_bib0350","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/09546634.2021.1942422","article-title":"The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis","volume":"33","author":"Miao","year":"2022","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2023.10.002_bib0355","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T Helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17\u2012type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0360","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/jdv.16246","article-title":"Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review","volume":"34","author":"Al-Janabi","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0365","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: a meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0370","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000503605","article-title":"A comparison of international management guidelines for hidradenitis suppurativa","volume":"237","author":"Hendricks","year":"2021","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2023.10.002_bib0375","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/bjd.17537","article-title":"British association of dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018","volume":"180","author":"Ingram","year":"2019","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0380","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: Part II: topical, intralesional, and systemic medical management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0390","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0395","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev Endocr Metab Disord."},{"key":"10.1016\/j.abd.2023.10.002_bib0400","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1203475417736290","article-title":"Hidradenitis suppurativa: a novel model of care and an integrative strategy to adopt an orphan disease","volume":"22","author":"Gulliver","year":"2018","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.abd.2023.10.002_bib0405","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1590\/abd1806-4841.20198607","article-title":"Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology","volume":"94","author":"Magalh\u00e3es","year":"2019","journal-title":"An Bras Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0410","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000477459","article-title":"Swiss practice recommendations for the management of hidradenitis suppurativa\/acne inversa","volume":"233","author":"Hunger","year":"2017","journal-title":"Dermatol Basel Switz."},{"key":"10.1016\/j.abd.2023.10.002_bib0415","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1203475417716117","article-title":"Approach to the management of patients with hidradenitis suppurativa: a consensus document","volume":"21","author":"Alavi","year":"2017","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.abd.2023.10.002_bib0420","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0425","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0430","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.abd.2023.10.002_bib0435","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0440","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0445","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biomedicines10061303","article-title":"Biologics and small molecule inhibitors for treating hidradenitis suppurativa: a systematic review and meta-analysis","volume":"10","author":"Huang","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.abd.2023.10.002_bib0450","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2018.1438269","article-title":"Pyoderma gangrenosum: a review of pathogenesis and treatment","volume":"14","author":"Ahn","year":"2018","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0455","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1159\/000519320","article-title":"Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review","volume":"238","author":"Ben Abdallah","year":"2022","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2023.10.002_bib0460","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/09546634.2018.1506083","article-title":"Biologic and small-molecule medications in the management of pyoderma gangrenosum","volume":"30","author":"McKenzie","year":"2019","journal-title":"J Dermatol Treat."},{"key":"10.1016\/j.abd.2023.10.002_bib0465","first-page":"290","article-title":"Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials","volume":"179","author":"Partridge","year":"2018","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0470","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut."},{"key":"10.1016\/j.abd.2023.10.002_bib0475","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/iwj.13067","article-title":"Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review","volume":"16","author":"Ben Abdallah","year":"2019","journal-title":"Int Wound J."},{"key":"10.1016\/j.abd.2023.10.002_bib0480","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in adults with steroid-refractory pyoderma gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0485","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1001\/archdermatol.2011.168","article-title":"Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab","volume":"147","author":"Guenova","year":"2011","journal-title":"Arch Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0490","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaip.2020.11.043","article-title":"Biologics for the use in chronic spontaneous urticaria: when and which","volume":"9","author":"Maurer","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.abd.2023.10.002_bib0495","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3796","article-title":"Global epidemiology of urticaria: increasing burden among children, females and low-income regions","volume":"101","author":"Peck","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0500","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI GALEN EDF WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy."},{"key":"10.1016\/j.abd.2023.10.002_bib0505","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2014.306","article-title":"Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study","volume":"135","author":"Saini","year":"2015","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100501","article-title":"Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both","volume":"14","author":"Chen","year":"2021","journal-title":"World Allergy Organ J."},{"key":"10.1016\/j.abd.2023.10.002_bib0515","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0520","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/all.15175","article-title":"Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy."},{"key":"10.1016\/j.abd.2023.10.002_bib0525","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0530","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.abd.2023.10.002_bib0535","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJMc2016395","article-title":"Benralizumab for chronic spontaneous urticaria","volume":"383","author":"Bernstein","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0540","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ddg.13481","article-title":"Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria","volume":"16","author":"Magerl","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.abd.2023.10.002_bib0545","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/cea.13616","article-title":"Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria","volume":"50","author":"Sabag","year":"2020","journal-title":"Clin Exp Allergy."},{"key":"10.1016\/j.abd.2023.10.002_bib0550","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0555","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology."},{"key":"10.1016\/j.abd.2023.10.002_bib0560","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0565","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs."},{"key":"10.1016\/j.abd.2023.10.002_bib0570","article-title":"Pemphigus vulgaris and bullous pemphigoid: update on diagnosis and treatment","volume":"10","author":"Di Lernia","year":"2020","journal-title":"Dermatol Pract Concept."},{"key":"10.1016\/j.abd.2023.10.002_bib0575","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet Lond Engl."},{"key":"10.1016\/j.abd.2023.10.002_bib0580","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0585","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/1744666X.2020.1672539","article-title":"Treatment of pemphigus vulgaris: part 2 - emerging therapies","volume":"15","author":"Yanovsky","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0590","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs."},{"key":"10.1016\/j.abd.2023.10.002_bib0595","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0600","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00403-004-0528-6","article-title":"Cytokine polymorphisms in patients with pemphigus","volume":"296","author":"Eberhard","year":"2005","journal-title":"Arch Dermatol Res."},{"key":"10.1016\/j.abd.2023.10.002_bib0605","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jid.2021.04.040","article-title":"Pemphigus and pemphigoid: from disease mechanisms to druggable pathways","volume":"142","author":"Ellebrecht","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.abd.2023.10.002_bib0610","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0615","doi-asserted-by":"crossref","DOI":"10.5070\/D3274053155","article-title":"Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature","volume":"27","author":"Saleh","year":"2021","journal-title":"Dermatol Online J."},{"key":"10.1016\/j.abd.2023.10.002_bib0620","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0625","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2022.5182","article-title":"Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus","volume":"159","author":"Kridin","year":"2023","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0630","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1177\/1203475421993779","article-title":"A systematic review of efficacy and safety of monotherapy and combination therapy with biologic for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"25","author":"Sachdeva","year":"2021","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.abd.2023.10.002_bib0635","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest."},{"key":"10.1016\/j.abd.2023.10.002_bib0640","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.burns.2014.01.027","article-title":"Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study","volume":"40","author":"Paquet","year":"2014","journal-title":"Burns."},{"key":"10.1016\/j.abd.2023.10.002_bib0645","article-title":"Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS\/TEN overlap syndrome","volume":"3","author":"Jacobsen","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.abd.2023.10.002_bib0650","first-page":"E15","article-title":"Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis","volume":"101","author":"Woolridge","year":"2018","journal-title":"Cutis."},{"key":"10.1016\/j.abd.2023.10.002_bib0655","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12016-021-08859-0","article-title":"Current perspectives on severe drug eruption","volume":"61","author":"Zhang","year":"2021","journal-title":"Clin Rev Allergy Immunol."},{"key":"10.1016\/j.abd.2023.10.002_bib0660","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jdcr.2019.07.004","article-title":"Drug-induced hypersensitivity syndrome with myocardial involvement treated with tofacitinib","volume":"5","author":"Damsky","year":"2019","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.abd.2023.10.002_bib0665","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaip.2017.10.020","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome successfully treated with mepolizumab","volume":"6","author":"Ange","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.abd.2023.10.002_bib0670","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1111\/jdv.15771","article-title":"Lichen planus: a comprehensive evidence-based analysis of medical treatment","volume":"33","author":"Husein-ElAhmed","year":"2019","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"key":"10.1016\/j.abd.2023.10.002_bib0675","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jid.2022.01.015","article-title":"Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective, open-label study","volume":"142","author":"Brumfiel","year":"2022","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0680","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3585","article-title":"Tofacitinib in hypertrophic lichen planus","volume":"100","author":"Seiringer","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.abd.2023.10.002_bib0685","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/12034754231156100","article-title":"The use of janus kinase inhibitors for lichen planus: an evidence-based review","volume":"27","author":"Abduelmula","year":"2023","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.abd.2023.10.002_bib0690","article-title":"Lichen planus","volume":"8","author":"Boch","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.abd.2023.10.002_bib0695","article-title":"Emerging therapies in cutaneous lupus erythematosus","volume":"9","author":"Sprow","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.abd.2023.10.002_bib0700","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0705","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.abd.2023.10.002_bib0710","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.abd.2023.10.002_bib0715","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","article-title":"A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo","volume":"81","author":"McKesey","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.10.002_bib0720","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0725","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40257-019-00428-8","article-title":"Biologic therapy in the treatment of cutaneous sarcoidosis: a literature review","volume":"20","author":"Dai","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0730","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/ijd.14350","article-title":"The role of biologics in the treatment of chronic granuloma annulare","volume":"58","author":"Chen","year":"2019","journal-title":"Int J Dermato."},{"key":"10.1016\/j.abd.2023.10.002_bib0735","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0740","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0745","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","article-title":"Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib","volume":"4","author":"Kim","year":"2018","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.abd.2023.10.002_bib0750","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/idoj.IDOJ_284_19","article-title":"Update on management of morphea (localized scleroderma) in children","volume":"11","author":"George","year":"2020","journal-title":"Indian Dermatol Online J."},{"key":"10.1016\/j.abd.2023.10.002_bib0755","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamadermatol.2018.5040","article-title":"A case of pansclerotic morphea treated with tocilizumab","volume":"155","author":"Zhang","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0760","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.abd.2023.10.002_bib0765","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.3390\/cells10082094","article-title":"Hidradenitis suppurativa: where we are and where we are going","volume":"10","author":"Scala","year":"2021","journal-title":"Cells."},{"key":"10.1016\/j.abd.2023.10.002_bib0770","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1529-8019.2008.01212.x","article-title":"Long-term safety of biologics in dermatology","volume":"22","author":"Lima","year":"2009","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.abd.2023.10.002_bib0775","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.13486","article-title":"Identification and Management of Psoriasis-Associated ComorbidiTy (IMPACT) Team. Psoriasis treatment and management - a systematic review of full economic evaluations","volume":"172","author":"Hamilton","year":"2015","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0780","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/bjd\/ljad003","article-title":"Assessing the use of biologic therapy for psoriasis in Latin America","volume":"188","author":"Bravo","year":"2023","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.abd.2023.10.002_bib0785","series-title":"Psoriasis treatment in Latin America: The Access Issue. 24th World Congress of Dermatology","author":"De la Cruz","year":"2019"},{"key":"10.1016\/j.abd.2023.10.002_bib0790","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjd.20428","article-title":"Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines","volume":"185","author":"Haw","year":"2021","journal-title":"Br J Dermatol."}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:00:51Z","timestamp":1747666851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059624000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":158,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0365059624000369"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2023.10.002","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted therapy for immune mediated skin diseases. What should a dermatologist know?","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2023.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.","name":"copyright","label":"Copyright"}]}}